Omeros Corporation (OMER)
| Market Cap | 237.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -140.04M |
| Shares Out | 57.95M |
| EPS (ttm) | -2.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,915 |
| Open | 4.140 |
| Previous Close | 4.150 |
| Day's Range | 4.050 - 4.180 |
| 52-Week Range | 1.050 - 5.680 |
| Beta | 1.48 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunog... [Read more]
Financial Performance
Financial StatementsNews
Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc...
Omeros Corporation Reports Second Quarter 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after ...
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, J...
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending th...
Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Off...
Omeros Corporation Reports First Quarter 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024...
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria sub...
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 202...
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell tr...
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded intere...
Omeros: Why It Is Worthwhile To Bet On Narsoplimab
Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and...
Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive O...
Omeros Corporation Reports Third Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, ...
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic st...
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pat...
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for...
Omeros to terminate kidney disease trial as therapy fails late-stage study
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
Omeros: Betting Big On Narsoplimab, We Are Still A Buyer
Omeros' "Buy" stance is based on upcoming developments in the second half of 2023-2024 around narsoplimab. OMER is expected to present a detailed analysis strategy for the narsoplimab BLA's reapplicat...
Omeros Corporation (OMER) Q2 2023 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Jennifer Williams - IR Gregory Demopulos - Co-Founder, Chairman, CEO & President Micha...